Questions to Ask Your Provider About Hormone Therapy

Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms of menopause -- hot flashes, night sweats, and the sleep disruption they cause. It can also address vaginal dryness, bone loss, and in some cases, mood symptoms. Yet the conversation around hormone therapy is often clouded by misinformation, outdated fears, and incomplete counseling.

The result is that many women either avoid hormone therapy entirely or accept it without fully understanding what they are taking, why, and what the monitoring plan should be. Neither outcome is ideal.

This article provides a framework of questions you can bring to your provider to ensure the conversation is thorough, individualized, and grounded in current evidence. These are not gotcha questions. They are the questions that a well-informed patient should be asking and that a competent provider should be prepared to answer.

Understanding the Basics

"What type of hormone therapy are you recommending, and why?"

Hormone therapy is not a single treatment. There are multiple formulations, routes of administration, and dosing strategies. The main categories include:

• Estrogen-only therapy (ET): Used for women who have had a hysterectomy. Since there is no uterus to protect, progesterone is not required.
• Combined estrogen-progesterone therapy (EPT): Required for women with an intact uterus. Progesterone protects the uterine lining from the proliferative effects of unopposed estrogen.
• Local (vaginal) estrogen: Low-dose estrogen applied locally for genitourinary symptoms. Minimal systemic absorption.

Within each category, there are choices about route (oral, transdermal patch, gel, spray, vaginal ring) and whether to use bioidentical or synthetic hormones. Each has trade-offs. Transdermal estrogen, for example, bypasses first-pass liver metabolism and carries a lower risk of blood clots compared to oral estrogen. Your provider should be able to explain why they are recommending one approach over another for your specific situation.

"What is the difference between bioidentical and synthetic hormones?"

This is one of the most confused topics in menopause care. "Bioidentical" means the hormone molecule is structurally identical to the hormone your body produces. "Synthetic" means it is a different molecular structure that produces similar effects. Both FDA-approved bioidentical and synthetic hormones have been studied in clinical trials.

What to watch out for: compounded bioidentical hormones (custom-mixed by a compounding pharmacy) are not FDA-regulated and lack the standardized testing that commercial products undergo. The Endocrine Society and NAMS do not recommend compounded hormones when an FDA-approved alternative exists.

Understanding Your Risk Profile

"What are the specific risks for someone with my medical history?"

Hormone therapy is not one-size-fits-all. The risk-benefit ratio depends on your age, time since menopause, personal medical history, and family history. Key risk factors that influence the decision include:

• History of breast cancer or strong family history
• History of blood clots (DVT, pulmonary embolism)
• History of stroke or cardiovascular disease
• Active liver disease
• Unexplained vaginal bleeding

The "timing hypothesis" -- supported by data from the WHI and subsequent studies -- suggests that hormone therapy initiated within 10 years of menopause onset or before age 60 carries a more favorable risk-benefit profile than therapy initiated later. Ask your provider where you fall on this timeline.

"How does hormone therapy affect my cardiovascular risk?"

This is where much of the confusion from the early 2000s WHI coverage originated. The original WHI headlines suggested hormone therapy increased heart disease risk. Subsequent re-analysis showed that the increased risk was concentrated in women who started therapy more than 10 years after menopause. For women who start within 10 years, the cardiovascular risk is neutral to potentially beneficial.

Your provider should be able to discuss how your individual cardiovascular risk factors -- blood pressure, lipids, smoking status, diabetes, family history -- interact with hormone therapy decisions.

"What about breast cancer risk?"

The relationship between hormone therapy and breast cancer is nuanced. Current evidence suggests:

• Estrogen-only therapy in the WHI was associated with a decreased risk of breast cancer over a median follow-up of 11 years.
• Combined estrogen-progestogen therapy was associated with a small increased risk, approximately 1 additional case per 1,000 women per year of use after 3 to 5 years.
• The type of progestogen may matter. Micronized progesterone appears to carry a lower risk than synthetic progestins like medroxyprogesterone acetate (MPA).

Ask your provider to put the absolute risk numbers in context. The per-year increase in breast cancer risk from combined HT is comparable to the increased risk associated with drinking two glasses of wine per day or being obese -- risks that are rarely discussed with the same urgency.

Dosing and Duration

"What is the lowest effective dose for my symptoms?"

Current guidelines recommend starting with the lowest dose that adequately controls symptoms. This minimizes potential side effects while still providing relief. Some women need standard doses; others do well on low or ultra-low doses. The right dose is the one that controls your most bothersome symptoms without unacceptable side effects.

"How long can I stay on hormone therapy?"

This is one of the most important and most poorly answered questions in menopause care. The outdated advice to "use the lowest dose for the shortest time" was based on early WHI interpretations and does not reflect current guidelines.

NAMS and the Endocrine Society now recommend individualized duration decisions based on ongoing symptom burden, risk factors, and patient preference. There is no arbitrary time limit. Some women benefit from hormone therapy for 5 years, some for 10, and some for longer. The decision should be reassessed periodically -- typically annually -- but "reassess" does not mean "stop."

"What happens if I stop? Can I restart?"

Symptoms often return when hormone therapy is discontinued, particularly vasomotor symptoms. Ask about tapering strategies versus abrupt cessation, and whether restarting is an option if symptoms recur. Your provider should have a plan for this contingency.

Monitoring and Follow-Up

"What monitoring will I need while on hormone therapy?"

Appropriate monitoring typically includes:

• An initial follow-up visit 4 to 8 weeks after starting therapy to assess symptom response and side effects
• Ongoing breast cancer screening (mammography) per age-appropriate guidelines
• Assessment of endometrial safety if you are on combined therapy (watching for unscheduled bleeding)
• Periodic reassessment of the risk-benefit ratio, typically annually
• Standard midlife health screenings: lipids, blood pressure, bone density as indicated

"How will we know if the therapy is working?"

This question gets at something important: you need measurable endpoints. "Feeling better" is a good start, but structured symptom tracking provides a more objective measure. If you are logging symptoms through a platform like Kairos™, you can compare your domain scores before and after starting therapy. This gives both you and your provider concrete data to evaluate treatment effectiveness.

Ask your provider what improvement they expect to see and in what timeframe. For vasomotor symptoms, most women notice significant improvement within 2 to 4 weeks. For bone density protection, the effect is gradual and measured over years via DEXA scans.

"When should I contact you between visits?"

Establish clear parameters for reaching out between scheduled appointments. Reasons to contact your provider include:

• Unscheduled vaginal bleeding
• Persistent breast tenderness or lumps
• Symptoms of blood clots (leg swelling, sudden shortness of breath, chest pain)
• Severe headaches, especially new-onset
• Side effects that are bothersome enough to affect adherence

Questions About Alternatives

"What if hormone therapy is not right for me?"

Not every woman is a candidate for hormone therapy, and not every woman wants it. Effective non-hormonal alternatives include:

• Fezolinetant (Veozah): A neurokinin-3 receptor antagonist approved in 2023 specifically for vasomotor symptoms. It works by a completely different mechanism than hormones.
• SSRIs/SNRIs: Particularly paroxetine (the only one FDA-approved for hot flashes) and venlafaxine. These can reduce hot flash frequency by 40 to 60 percent.
• Gabapentin: Particularly useful when hot flashes are predominantly nocturnal.
• Cognitive behavioral therapy (CBT): Evidence supports CBT for both vasomotor symptoms and menopause-related insomnia.
• Vaginal moisturizers and lubricants: For genitourinary symptoms when systemic or even local hormones are not an option.

Ask your provider which alternatives have the strongest evidence for your specific symptom profile.

The Meta-Question

"Are you comfortable managing hormone therapy, or should I see a specialist?"

This is a fair and important question. Not all primary care providers or gynecologists have extensive menopause training. NAMS-certified menopause practitioners have demonstrated competency in this area. If your provider seems uncertain or defaulting to overly conservative positions without clinical justification, a referral to a menopause specialist may be warranted.

A good provider will not be offended by this question. They will either reassure you of their expertise or facilitate a referral. Either outcome serves your interests.

Bringing It Together

The hormone therapy conversation should be a dialogue, not a monologue in either direction. You bring knowledge of your body, your symptoms, your values, and your risk tolerance. Your provider brings clinical expertise, knowledge of current evidence, and the ability to individualize treatment recommendations.

These questions are designed to make that dialogue more productive. Print them out, bring them to your appointment, and do not apologize for being prepared. Informed patients get better care.